Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Earnings Neutral

Conavi Medical Reports Fiscal Second Quarter 2026 Results and Operational Highlights

FDA Clearance Delivered But Dilution and Cash Burn Threaten Near-Term Stability

By The Northwire Desk — AI Analysis May 28, 2026 · 08:00 CNVI · 0.275 Conavi Medical Corp.
Executive Summary
  • Conavi Medical Corp. reported Fiscal Q2 2026 results with $0.1 million in licensing/R&D revenue and a net loss of $4.8 million.
  • Cash reserves stood at $4.5 million as of March 31, 2026, down from $5.8 million six months prior.
  • The company received U.S. FDA 510(k) clearance for its Novasight Hybrid IVUS-OCT system on April 20, 2026.
  • A proposed public offering of common shares and/or pre-funded warrants was announced May 11, 2026, with an expected closing date of May 28, 2026.
  • Proceeds from the financing are intended to fund U.S. commercial launch activities, working capital, and general corporate purposes.
  • The company received industry awards (MedTech Breakthrough Awards, TAG Innovation Award) recognizing its technology.
Material Impact
  • Regulatory Milestone: FDA clearance was anticipated in H1 2026 per February guidance; therefore, this is not unexpected news but confirms execution of the roadmap. It enables commercial launch but does not guarantee immediate revenue.
  • Financial Performance: The net loss of $4.8 million for Q2 indicates a burn rate exceeding cash reserves ($4.5M). Without the May financing closing, the company faces a liquidity crisis within one quarter.
  • Financing Risk: The proposed offering introduces significant dilution risk. The stock price has already reacted negatively to this announcement (dropping from $0.48 in April to $0.28 in late May), suggesting market skepticism regarding valuation and dilution.
  • Commercialization: Revenue remains negligible ($0.3M for six months). Commercial launch is targeted for H2 2026, meaning the company will likely continue burning cash without product revenue for several more quarters.
  • Overall Impact: The news confirms regulatory progress but highlights severe capital constraints. The financing is necessary for survival but dilutive. Given expectations were met (clearance) and financials are consistent with pre-revenue burn, the impact on fundamentals is neutral to negative due to cash runway concerns.
CNVI · Price
Company Overview
  • Company: Conavi Medical Corp., a medical technology company focused on intravascular imaging.
  • Flagship Project: Novasight Hybrid IVUS-OCT Imaging System. Integrates Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) into a single system for simultaneous coronary artery imaging.
  • Development Status: First-generation system cleared in U.S., Canada, China, Japan. Next-generation system received FDA 510(k) clearance on April 20, 2026.
  • Clinical Validation: Peer-reviewed study published in Cardiovascular Research demonstrated superior plaque characterization using hybrid deep-learning classifier versus single-modality imaging and expert readers.
Read the original news release →

More from Conavi Medical Corp.

Jun 29, 2026 · 07:00

Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund

Financings May 11, 2026 · 07:00

Conavi Medical files for fresh equity offering as cash reserves dwindle ahead of U.S. Novasight launch, raising dilution fears amid a share price plumbing near all-time lows.

Financings Apr 23, 2026 · 07:00

Conavi Medical Awarded 2026 TAG Innovation

Regulatory Apr 20, 2026 · 07:00

FDA Clearance Confirms Timeline, But Cash Burn Threatens Commercial Launch Viability

Regulatory Feb 26, 2026 · 07:05

Conavi Medical Reports Fiscal First Quarter 2026 Results and Operational Highlights

Financings Feb 13, 2026 · 12:29

Conavi highlights hybrid IVUS-OCT study results

Production / Operations